Find your path to erick
506 people in our graph share verified history with erick — schools, employers, funds. One of them is your warm intro.
Michèle Ollierunlockederick: together at Université Paris Cité (1984–1985)
×6erick: together at Amgen
×2erick: together at Université Paris Cité
×2erick: together at Pfizer
About
Erick Gamelin is Chief Development Officer at Acrivon Therapeutics, where he led the company's 2022 NASDAQ IPO that raised $94 million. He has more than 30 years of experience across academia, pharmaceutical companies, and biotech, holding roles including CEO, CMO, and CDO, and has directed oncology and immunology programs that gained FDA and EMA approvals for treatments such as PEG-filgrastim, romiplostim, denosumab, blinatumomab, and panitumumab. Gamelin previously served as CEO of the Institut de Cancérologie de l'Ouest in France, managing 1,000 employees and a €100M budget, and was awarded the French National Order of Merit.
Executive at Acrivon Therapeutics
Intro paths
→
In turn, erick can intro founders to Acrivon Therapeutics's investors below.
Acrivon Therapeutics's investors · 3
Co-founders at Acrivon Therapeutics
PB
Peter Blume-JensenExecutive Officer, Director
KM
Kristina MassonExecutive Officer, Director
Experience
- Acrivon TherapeuticsChief Development Officer (CDO)2024 — 2026Watertown, Massachusetts, United States
- Acrivon TherapeuticsChief Medical Officer2021 — 2023Watertown, Massachusetts, United States
- Elicio TherapeuticsOncology Vaccine Consultant2020 — 2026San Francisco, California, United States
- Voisin Consulting Life Sciences (VCLS)Senior Consultant2019 — 2022
- innoHealth GroupStrategic Advisor2020 — 2021Hong Kong SAR
- Arrowhead PharmaceuticalsOncology Consultant2020 — 2021Pasadena, California, United States
- Step PharmaChief Medical Officer2020 — 2021Geneva, Switzerland
- Dynavax TechnologiesVice President Oncology2018 — 2019Emeryville, California, United States
- MacroGenics, Inc.Vice President Clinical Research2017 — 2018Rockville, Maryland
- PfizerExecutive Director, Medical Sciences, Early Development Leader, Oncology-Hematology2015 — 2017San Diego County, California, United States
- AmgenMedical Director Medical Sciences Early Development Leader2011 — 2015Los Angeles Metropolitan Area
- AmgenMedical Director Oncology-Hematology Medical Affairs2009 — 2011Greater Paris Metropolitan Region
- University of Angers Pays de LoireProfessor of Medical Oncology2000 — 2011Angers Pays de Loire, France
- University Cancer CenterChief Executive Officer2005 — 2009Paul Papin Regional Cancer Center, France
- University Cancer CenterOncogenomics-Biomarkers laboratory Director1989 — 2009Angers Area France
Skills & more
Cross-functional Team Leadership1Oncology21Clinical Trials17Immunology10Clinical Research8Clinical Development9Pharmacology8Molecular Biology5Medicine4Cell3Hematology3Drug Development
+12 more
U.S. Food and Drug Administration (FDA)Translational MedicineClinical PharmacologyTranslational ResearchBiomarkersEarly DevelopmentMedical AffairsPharmacokineticsStrategyINDEMAOncology Therapeutic landscape and competitionLanguages English · French
From erick's professional profile.
Frequently asked questions
- Who is erick gamelin?
- Erick Gamelin is Chief Development Officer at Acrivon Therapeutics, where he led the company's 2022 NASDAQ IPO that raised $94 million. He has more than 30 years of experience across academia, pharmaceutical companies, and biotech, holding roles including CEO, CMO, and CDO, and has directed oncology and immunology programs that gained FDA and EMA approvals for treatments such as PEG-filgrastim, romiplostim, denosumab, blinatumomab, and panitumumab. Gamelin previously served as CEO of the Institut de Cancérologie de l'Ouest in France, managing 1,000 employees and a €100M budget, and was awarded the French National Order of Merit.
- Where did erick gamelin go to school?
- erick gamelin studied at UC Berkeley Extension (Certificate, CRISPR-Cas); Université d'Angers (professor, Medical Oncology Residency Program); NCI-NIH (Post-Doc, Cancer Biology: resistance mechanisms).
Same school
Also attended UC Berkeley Extension35
Robert LindseyInvestor at Initialized CapitalHerme EdolmoCFO at G Vision CapitalAshley WhitehurstChief of Staff at Mighty CapitalDevon MorrisPartner at Group 11Mitty ChangChief Growth Officer & Operating Partner at Sora VenturesSolene FeuilluPrincipal | Capital Formation at Borderless Venture
+ 29 more
Also attended Université d'Angers4
Also attended Université de Bordeaux41
Jeff PomeranzManaging Director at RSCMMarc WeillVC Analyst Intern at OneRagtimeBrice LapoublePartner at Axeleo CapitalOlivier DubuissonManaging Partner at KaristaAlessio PiumaInvestment Manager at Panakes PartnersGuy BentleyInvestor at Crane Venture Partners
+ 35 more
Also attended Université Paris Cité117
Michèle OllierInvestor at MedicxiMaija MuntilaTalent Lead at Lifeline VenturesZach WhiteInvestment Team at 8VCCyril CollonGeneral Partner at Partech VenturesIsabelle TressonCommunications & Marketing Lead at Partech VenturesBeryl BouchierVice President at Sky9 Capital
+ 111 more
Shared employers
Also worked at Elicio Therapeutics1
Also worked at Arrowhead Pharmaceuticals5
Also worked at Step Pharma2
Also worked at MacroGenics, Inc.8
Kenneth GalbraithInvestor at SynconaPaul SekhriInvestor at eGenesis, Inc. Full-timeAlfred ScheideggerManaging Partner at Nextech InvestOri WarshavskyExecutive Officer at PolyPidFederica F. O'BrienExecutive Officer at Cerecor Inc.Bob LechleiderChief Medical Officer at Immunome
+ 2 more